replimune.com - REPL Net Assets per Single Share

Replimune Group, Inc. (REPL) management is currently restructuring internal processes to prepare for the results of critical tests while maintaining investor confidence. High barriers to entry in the viral platform niche and patent protection limit competition. The current metric stands at 1.27. This price chart on GURU.Markets confirms that business success relies on the efficiency of the Immulytic system and free capital volumes.

REPL: Replimune Corp Net Asset Value per Share 07/04/2022 - 10/27/2026

replimune.com - analytical breakdowns and key metrics (REPL)

- price and consensus price forecast:

Price Chart Replimune Corp|REPL - Forecast Levels Chart

- market capitalization data:

Market Value Replimune Group, Inc.|REPL - Total Company Value

- book capitalization data:

Net Assets per Single Share Replimune|REPL - Total Stockholders' Equity|Market Value to Book Value Ratio replimune.com|REPL - Total Business Assets

- debt and liquidity data:

Total Debt to Capital Replimune Group, Inc.|REPL - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Replimune|REPL - Company Cumulative Debt|Debt to Book Capitalization Ratio Replimune Group, Inc.

Fundamental company valuation:REPL - Replimune Corp

To identify the sector's fundamental leaders, the analyst evaluates net asset value per share, which determines the value of assets in a hypothetical business liquidation and establishes a price support floor. In the case of Replimune Group, Inc. (REPL), investments in robotic laboratories for biomolecule screening directly impact the tangible asset base, which is reflected in the trend of the target book value per share.

Competitor analysis for Replimune Group, Inc.